Compare OC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | CYTK |
|---|---|---|
| Founded | 1938 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.4B |
| IPO Year | 2006 | 2004 |
| Metric | OC | CYTK |
|---|---|---|
| Price | $128.11 | $78.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | ★ $145.27 | $89.26 |
| AVG Volume (30 Days) | 968.2K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $3.72 | $310.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $97.53 | $31.99 |
| 52 Week High | $159.42 | $80.20 |
| Indicator | OC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 62.37 |
| Support Level | $114.43 | $59.07 |
| Resistance Level | $129.53 | $79.66 |
| Average True Range (ATR) | 4.61 | 3.20 |
| MACD | 0.73 | 0.51 |
| Stochastic Oscillator | 78.64 | 83.65 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.